Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON)...
39 insider purchases on record · latest filing 2024-12-09.
Insiders have also filed 402 sale transactions at RVMD.